Every letter we have printed

The tolerability profile of a multi-receptor compound is not the sum of the single-target profiles either, and it is discussed as though it were. Both directions of that assumption are unsupported.

Whether a second activity contributes at the exposures actually achieved is an empirical question separate from whether it exists in an assay. A weak activity at high concentration may be pharmacologically irrelevant in practice.

The structural work on this receptor is now good enough to explain several of the selectivity differences that used to be empirical observations. It is a genuine advance and it has not reached the popular accounts at all.

Your blind duplicate exercise is the most valuable thing this publication does, and eight vials is not enough to carry the conclusion you drew from it. Without replicates within each laboratory you cannot separate between-laboratory variation from vial-to-vial variation, and the honest reading is that four figures differed.

Blind means the analyst does not know the origin. It does not mean the analyst does not know the expected answer, and for a common molecule at a common strength they will. That is a second blinding nobody attempts and it is not obvious it can be attempted.

Turnaround is the specification buyers actually choose on, and it is the one that quietly sets the method. A service promising a result within days is promising a short generic gradient, because nothing else fits the queue. Price and turnaround are method disclosures in disguise.

A structural suggestion. If the services published the count of reports issued to each requester alongside the count published by that requester, the selective-publication problem would be visible without disclosing a single result. It is a number they already have.

External calibration performed at the start of a batch will drift over a working day on some instruments. A laboratory quoting accuracy to a few parts per million on a sample run eleven hours after calibration is quoting a specification rather than a measurement, unless a lock mass was used.

A note on calibration intervals. Mass accuracy drifts with laboratory temperature, and a determination run eight hours after the last calibration is a different measurement from one run eight minutes after it. The interval is recorded in the instrument log and never in the report.

The leucine and isoleucine problem is the cleanest illustration of your argument. They are the same mass, they are different residues, and no amount of accuracy on the intact molecule will separate them. Sequence confirmation requires fragmentation and, for that particular pair, a fragmentation method most services do not run.

Counter-ion mass is the quiet arithmetic error in this market. A buyer weighing out a trifluoroacetate salt as though it were free peptide is short by a margin that varies with the number of basic residues. It is invisible to every method described in your series and it changes what is in the vial.

I read this twice, which is unusual, and the second reading was the useful one. Whatever the desk is doing with structure at the moment is working.

Scope is the part that most misleads. A badge earned on one molecule appears on a page listing forty, and readers reasonably take the mark as a statement about the seller rather than about the sample. Nothing on the badge disclaims the wider reading.

The graphic language is borrowed from certification marks in other industries, where a mark means an audited and continuing arrangement. Here it means a single paid determination. The visual grammar has been imported and the meaning behind it has not.

Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.

The strongest blind design I have seen anywhere involved a third party holding the purchase record, the laboratory receiving numbered tubes and the mapping opened only after all results were in. It is not expensive. It is simply organisation, and organisation is what this market lacks.

The spread you reported is, by the standards of interlaboratory comparison in sectors I have worked in, unremarkable. That is not a criticism of your reporting; it is a correction to the alarm some readers will take from it. Two laboratories differing by a point on a chromatographic purity are behaving normally.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

Placement carries meaning. A mark beside a price reads as a claim about that product; the same mark in a footer reads as a claim about the company. Sellers know this and choose accordingly, and no rule anywhere governs the choice.

A note on scale. One of these services runs volumes that would be respectable for a contract laboratory in a regulated sector; another is a small operation with a short queue. Both issue documents that look alike and carry the same weight in a listing. The report format equalises what the operations do not.

Reconstituting with the wrong volume and then calculating from the intended volume is the second error, and it is invisible afterwards because the vial looks identical. Writing the actual diluent volume on the vial with a marker takes three seconds and closes it.

Designing the error out is more effective than warning about it, which is the settled conclusion of every human-factors literature. In this market nobody controls the design, so the only available lever is the weakest one.

Reconstitution before submission destroys the custody argument entirely, and buyers do it because a solution is easier to post than a vial. The convenience is real and it converts a question about a product into a question about a preparation.

Third-party custody is the answer and nobody will pay for it. A freight agent or a bonded store can hold and forward samples with a signed record for a modest fee, and I have never seen it used in this trade once.

You disclose that two of these services advertise with you and then spend four thousand words on structural criticism of the sector they operate in. I cannot decide whether that is admirable independence or an elaborate way of appearing independent. Probably the former. I wanted to say that I noticed the question.

I asked four suppliers about this last year and all four answered plainly that it is not part of the standard panel and can be quoted separately. The silence is on the storefront rather than in the correspondence.

Community discussion is dominated by what can be verified cheaply, and verification cost determines which topics are live. This one has no cheap verification available to an individual, so it does not become a topic.

An interlaboratory comparison needs a homogeneous material and a stated assigned value, which is why proficiency schemes in other sectors are run by a body that prepares the material rather than by a participant. Until somebody does that here, these exercises measure agreement rather than accuracy.

The word independent is used for two different things: independence of ownership and independence of the sample. A service can be entirely independent commercially and still be testing material the seller handed it, and readers hear the first and assume the second.

A participant who is scanned is not a random participant. Substudy enrolment depends on site capability and on willingness, and the resulting sample can differ from the trial population in ways nobody records. It is a small caveat and it belongs in the methods paragraph.

Where the same substudy is reported twice, once in the primary publication and once in a later analysis, the figures sometimes differ slightly for entirely legitimate reasons. Coverage then cites whichever it found first and the discrepancy becomes an argument.

Your piece treats the one-quarter rule as discredited and then quotes fractions of one third and two fifths from the substudies as though those were more solid. They are group means from a hundred and forty people. Physician, heal thyself.

The ratio everybody quotes was measured in a population with a mean age and a mean starting composition, and it is applied without adjustment to people well outside both. Every term in that extrapolation is doing work that the original authors would not endorse.

Baseline composition determines a great deal of what follows, and it is the variable most often omitted from the summary. Two people losing the same mass from different starting compositions have not had the same experience.

Where a trial protocol offered activity advice rather than a programme, the coverage reports it as a training intervention. Advice and supervision are different interventions with different effect sizes.

Where a study reported no benefit from an activity component, the usual explanation offered is adherence rather than efficacy, and adherence was measured by self-report. That explanation may be right and it is not supported by the data used to make it.

Function is what people care about and composition is what was measured. The step from one to the other is an extrapolation that the papers do not make and the coverage makes constantly.

Timing of the final scan relative to the last dose varies between studies and is not always reported. Fluid shifts on that timescale are large enough to matter for a lean-mass measurement.

Where the scan schedule differed between arms for practical reasons, the comparison acquires a timing confound that no adjustment removes. It is described in the methods of at least one of these papers and never in the coverage.

The commercial literature describes maintenance as a phase; the trial literature describes it as an extension arm; the people I correspond with describe it as the rest of their life. Three timescales, one word, and most confusion in this area comes from the mismatch.